Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06624592 · ClinicalTrials.gov registry record · Phase 3
Sevoflurane/Dexmedetomidine vs. Isoflurane for Pediatric Emergence Delirium
A Phase 3 study of Delirium on Emergence, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT06624592 is a Phase 3 study of Delirium on Emergence that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 400 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06624592, a Phase 3 study of Delirium on Emergence, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the incidences of pediatric emergence delirium between the group receiving Isoflurane and the group receiving Sevoflurane plus intravenous push dexmedetomidine.
Conditions Studied
Interventions
- DRUG Sevoflurane
- DRUG Isoflurane
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06624592
The ClinicalTrials.gov registry entry for NCT06624592 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Delirium on Emergence appearing as the primary indexed condition, and to 2 interventions - of which Sevoflurane is the first listed.
NCT06624592 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06624592 about?
NCT06624592 is a clinical study titled "Sevoflurane/Dexmedetomidine vs. Isoflurane for Pediatric Emergence Delirium". The purpose of this study is to measure the incidences of pediatric emergence delirium between the group receiving Isoflurane and the group receiving Sevoflurane plus intravenous push dexmedetomidine.
What is the current status of trial NCT06624592?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2024-12-20. Estimated completion is 2026-11-01.
What conditions does trial NCT06624592 study?
This clinical trial studies the following conditions: Delirium on Emergence.
What interventions are being tested in trial NCT06624592?
The interventions under investigation include: Sevoflurane (DRUG), Isoflurane (DRUG).
Who is sponsoring clinical trial NCT06624592?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06624592 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.